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Ubiquitination regulates, via different modes of modiﬁcations,
a variety of biological processes, and aberrations in the process
have been implicated in the pathogenesis of several neurodegen-
erative diseases. However, our ability to dissect the pathophysi-
ological relevance of the ubiquitination code has been hampered
due to the lack of methods that allow site-speciﬁc introduction of
ubiquitin (Ub) chains to a speciﬁc substrate. Here, we describe
chemical and semisynthetic strategies for site-speciﬁc incorpora-
tion of K48-linked di- or tetra-Ub chains onto the side chain of
Lys12 of α-Synuclein (α-Syn). These advances provided unique op-
portunities to elucidate the role of ubiquitination and Ub chain
length in regulating α-Syn stability, aggregation, phosphorylation,
and clearance. In addition, we investigated the cross-talk between
phosphorylation and ubiquitination, the two most common α-Syn
pathological modiﬁcations identiﬁed within Lewy bodies and Par-
kinson disease. Our results suggest that α-Syn functions under com-
plex regulatory mechanisms involving cross-talk among different
posttranslational modiﬁcations.
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One of the most common posttranslational modiﬁcations ineukaryotes is the covalent attachment of ubiquitin (Ub) to
proteins. This reversible modiﬁcation, which regulates a variety
of biological processes, such as protein degradation, trafﬁcking,
and DNA damage response (1, 2), involves the attachment of the
C terminus of Ub mainly to the side chain of a Lys residue in a
protein substrate via an isopeptide linkage. The process is catalyzed
by three enzymes that act in concert: the Ub-activating enzyme
(E1), the Ub-conjugating enzyme (E2), and the Ub ligase (E3).
The reaction is repeated, and a second Ub is attached to an in-
ternal Lys in the previously conjugated ubiquitin. Several repeats
result in the synthesis of a poly-Ub chain that can be of varying
lengths and internal linkages. The presence of seven Lys residues
as possible anchoring sites within Ub in addition to the N-terminal
amine results in a highly complex landscape of diverse Ub bio-
conjugates, which accounts for the diversity of the Ub signaling (3).
Research in the Ub ﬁeld, which aims at understanding the
ubiquitination system at the molecular level, has been hampered
by the difﬁculties of controlling ubiquitination in the cell and
challenges associated with the preparation of speciﬁc Ub con-
jugates in vitro. These limitations have inspired the development
of novel synthetic strategies to facilitate site-speciﬁc ubiquitina-
tion of proteins (4, 5). Recent advancements in the ﬁeld have
enabled the synthesis of relatively large amounts of highly com-
plex Ub conjugates of deﬁned covalent structure and provided
novel insights into the structural, biochemical, and functional con-
sequences of protein ubiquitination, along with unique opportuni-
ties to elucidate the molecular basis of Ub signaling. For example,
monoubiquitinated α-Synuclein (α-Syn) and histone H2B bearing
native isopeptide bonds were prepared and used to shed light
on the role of monoubiquitination in regulating α-Syn aggrega-
tion and degradation by the proteasome (6, 7) and histone H2B
functions within the nucleosomal context (8). Successful syn-
thesis of all Lys-linked di-Ub chains with native isopeptide bonds
were also achieved and proved to be instrumental in studies aimed
at understanding the structures and dynamics of these chains, as
well as their relative sensitivities towards deubiquitinases (9, 10).
These advances provided access to new structural information
about K33- and K6-linked di-Ub chains using NMR and X-ray
crystallography, respectively (11, 12). More recently, tetra-Ub
chains in a free form or anchored to a tripeptide were also
synthesized chemically (13–15).
Despite these important achievements, one of the most im-
portant synthetic targets in these endeavors, the synthesis of
homogeneous and well-deﬁned polyubiquitinated proteins, has
remained out of reach. Success in preparing these highly chal-
lenging targets is crucial for dissecting the effects of poly-Ub
chain lengths and the role of a particular Ub chain in regulating
protein structure and function in different cellular pathways.
Toward achieving this goal, we sought to expand our tools and
synthetic methodologies to enable the preparation of di- and tet-
raubiquitinated proteins in sufﬁcient quantities for biophysical,
biochemical, and cellular studies.
Signiﬁcance
This study describes the nonenzymatic preparation of a protein
conjugated to a tetraubiquitin Lys48-based chain made of native
isopeptide bonds. We show that certain properties of our model
protein, the Parkinson disease-associated protein α-Synuclein
(α-Syn), are differentially regulated depending on the length of
the conjugated ubiquitin (Ub) chain. In addition, we show that
cross-talksbetweenphosphorylationandubiquitinationmayplay
important roles in regulating α-Syn aggregation and pathophys-
iology. The versatile synthetic strategydescribed herewill enable
future studies to further dissect the roles of Ub chain lengths
and linkage types, conjugated in a site-speciﬁc manner, in reg-
ulating the physiological and pathological functions of α-Syn
and other proteins.
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Here, we report a semisynthetic strategy that enables site-
speciﬁc conjugation of poly-Ub chains and generation of di- and
tetraubiquitinated proteins of well-deﬁned covalent structure.
We focused our efforts on the conjugation of di- and tetra-Ub
chains, because the effect of the chain length in protein degradation
remains poorly understood and a tetra-Ub chain is proposed to be
the shortest and minimal signal required for recognition and tar-
geting of proteins for proteasomal degradation (16).
As a model system, we chose α-Syn, a 140-residue intrinsically
disordered presynaptic protein that plays a central role in the
pathogenesis of Parkinson disease (PD) and several other neu-
rodegenerative diseases (collectively known as synucleino-
pathies). In diseased brains, α-Syn self-associates to form ﬁbrillar
aggregates, which are the primary constituents of Lewy bodies
(LBs), the pathological lesions that deﬁne PD. LBs are immu-
noreactive for Ub (17, 18), and biochemical analyses of α-Syn
puriﬁed or immunoprecipitated from LBs or insoluble α-Syn
preparations (19) from a patient who had dementia with LBs
demonstrated evidence for mono-, di-, tri-, and polyubiquitinated
forms of the protein (17, 20). Similar ubiquitinated α-Syn species
were also reported in cell culture models of synucleinopathies (17)
and in in vitro ubiquitination assays (21, 22). Recent studies from
our laboratories (6), which were independently conﬁrmed by
Meier and colleagues (23), demonstrated that monoubiquitination
inhibits rather than promotes α-Syn ﬁbrillization. These ﬁndings
suggested that ubiquitination may play an important role in α-Syn
aggregation and LB formation. However, very little is known
about the effect of poly-Ub chain length on α-Syn aggregation and
degradation or on how the pattern of ubiquitination [i.e., linkage
type, anchoring site(s)] may inﬂuence the functional and patho-
genic properties of α-Syn.
In this study, we describe chemical and semisynthetic strate-
gies that enabled site-speciﬁc incorporation of K48-linked di- or
tetraubiquitin chains onto the side chain of Lys12 of α-Syn.
These advances provided unique opportunities to elucidate the
role of ubiquitination in regulating α-Syn stability, aggregation,
and clearance, and to investigate cross-talk between the two most
common α-Syn pathological modiﬁcations found within LBs,
phosphorylation and ubiquitination. Our results demonstrate
that the length of the Ub chain plays an important role in reg-
ulating α-Syn ﬁbril formation, phosphorylation, and clearance,
and suggest that α-Syn structure, function, and pathophysiology
could be under complex regulatory mechanisms involving cross-
talk among different posttranslational modiﬁcations.
Results
Chemical Synthesis and Puriﬁcation of Di- and Tetraubiquitinated
α-Syn. Although the syntheses of monoubiquitinated proteins
and free di- and tetra-Ub chains have been accomplished (6, 10,
15), the synthesis of di- or tetraubiquitinated proteins has
remained out of reach. Such synthesis requires site-speciﬁc and
efﬁcient coupling of the Ub chain to the desired residue in the
protein of interest. In this study, we sought to determine the
effect of K48-linked di- and tetra-Ub chains into the side chain of
Lys12 on the biochemical properties of α-Syn. We chose to in-
corporate these Ub chains at position K12 in α-Syn because this
residue was shown to be ubiquitinated in α-Syn isolated from LBs
(20). However, the approach described here can be easily applied
to conjugate poly-Ub chains at other putative ubiquitination sites
in the N-terminal region of the protein.
We envisioned the development of semisynthetic approaches
that allow the generation of di- and tetraubiquitinated forms of
α-Syn via the incorporation of our δ-mercaptolysine at the de-
sired lysine residue (24). We ﬁrst synthesized α-Syn bearing a
δ-mercaptolysine at K12 (K*12), using a chemically synthesized
α-Syn(1–29)–thioester peptide and recombinant α-Syn(30–140)
fragment harboring N-terminal Cys (Fig. 1) that was expressed in
Escherichia coli and puriﬁed as described in SI Materials and
Methods. This led to a more efﬁcient synthesis of α-Syn[(1–140)-
(K12K*)], compared with the previously described methods for
the synthesis of α-Syn[(1–140)-(K6K*)] (6). This was due to our
ability to prepare the thioester peptide [i.e., α-Syn(1–29)-thio-
ester] using Fmoc-solid phase peptide synthesis, which allowed
the use of the thiazolidine (Thz)-protected form of δ-mercap-
tolysine, hence enabling in situ deprotection of the δ-mercap-
tolysine subsequent to the native chemical ligation step (25).
Previously, we used the acetamidomethyl (Acm)-protected ver-
sion of δ-mercaptolysine (6), which required the isolation of the
ligation product to remove the Acm protecting group.
Next, we turned our attention to the most challenging aspect
of the preparation of tetraubiquitinated α-Syn, namely the at-
tachment of the K48-linked tetra-Ub chain, composed of 304
residues, to K*12 of α-Syn. This could, in principle, be achieved
by preparing tetra-Ub–thioester for isopeptide chemical ligation
(ICL) with α-Syn–bearing δ-mercaptolysine. However, several
attempts to prepare the tetra-Ub–thioester using N-methyl-
cysteine–mediated latent thioester formation (26) were un-
successful. Despite being able to prepare the tetra-Ub chain with
the proximal Ub having N-methylcysteine, we failed to identify
conditions that allow efﬁcient thioester formation. As an alter-
native approach, we envisioned the preparation of two different
fragments of di-Ub–thioester, followed by two sequential ligation
steps with α-Syn (Fig. 1). Here, the N-methylcysteine–mediated
latent thioester formation was successful and enabled the prep-
aration of Ub2-Ub1-thioester and Ub4-Ub3-thioester in high
yields, sufﬁcient for the ligation with α-Syn[(1–140)-(K12K*)].
Hence, α-Syn[(1–140)-(K12K*)] was ligated with Ub2-Ub1-thio-
ester to give diubiquitinated α-Syn(1–140), Ub1,2-Syn(1–140), in
good yield, which was then subjected to methoxylamine treat-
ment at pH 4 to expose the δ-mercaptolysine for the subsequent
Fig. 1. Semisynthesis strategy for the preparation of di- and tetraubiquiti-
nated α-Syn. The scheme shows how tetra-Ub–α-Syn was assembled from the
recombinant fragment α-Syn[30–140(A30C)], the synthetic fragment α-Syn(1–
29) K12K* thioester, and two synthetic diubiquitin thioester building blocks.
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ICL with Ub4-Ub3-thioester. The latter ligation also proceeded
efﬁciently, as indicated by the disappearance of the Ub4-Ub3-
thioester and the formation of tetraubiquitinated Syn(1–140),
Ub1,2,3,4-Syn(1–140), as a major product, as evidenced by HPLC-
MS and SDS/PAGE analyses. The ligation mixture was then
subjected to desulfurization using radical-based conditions [Tris
(2-carboxyethyl)phosphine (TCEP), 2,2′-Azobis[2-(2-imidazolin-
2-yl)propane]dihydrochloride (VA-044), and 2-methylpropane-
2-thiol] (27), which was completed after 12 h (Fig. 2D and Fig. S1B).
To be able to study the effect of α-Syn di- or tetraubiquitination
at K12, we attempted ﬁrst to separate the two species from the
unreacted materials [more speciﬁcally, Ub1,2-Syn(1–140) and the
unconjugatedα-Syn].After exploring several techniques, we found
that only the use of gel-eluted liquid fraction entrapment elec-
trophoresis (28), amolecular-weight–based puriﬁcation technique
akin to preparative SDS/PAGE, allowed the separation and iso-
lation of highly pure (>95%) di- and tetraubiquitinated α-Syn (Fig.
2A). Western blot analysis conﬁrmed that the puriﬁed proteins
could be recognized by antibodies speciﬁc for anti–α-Syn and anti-
Ub (Fig. 2B). We then veriﬁed the folding state of di- and tet-
raubiquitinated α-Syn by CD spectroscopy. TheCD spectra shown
in Fig. 2C are consistent with those of the correctly folded Ub and
Ub chains as determined by comparison with previously published
CD spectra of unanchored di- and tetra-Ub (10, 15), and they
suggest that the α-Syn moiety remains unstructured, as previously
observed with monoubiquitinated α-Syn at K6 (6).
Tetraubiquitinated α-Syn Forms Soluble but SDS-Resistant High-
Molecular Weight Aggregates. Although polyubiquitinated α-Syn
species have been detected in LBs and insoluble α-Syn–rich frac-
tions from human brains, the role of poly-Ub in α-Syn aggregation
and LB formation remains unknown. To examine the effect of
Ub chain length on α-Syn ﬁbril formation, we compared the
aggregation propensities of WT and K12 tetraubiquitinated
α-Syn. The in vitro ﬁbrillization studies were carried out at a low
protein concentration (5 μM), to mimic to the best possible ex-
tent the estimated physiological concentration of α-Syn in neu-
rons (∼1 μM) (29). At lower concentrations, α-Syn does not form
ﬁbrils readily in vitro. Using a Western blot assay, we monitored
the amount of soluble protein during incubation at 37 °C with
shaking. Under these conditions, WT α-Syn remains completely
soluble (Fig. 3A) while tetraubiquitinated α-Syn rapidly forms
soluble but SDS-resistant high-molecular weight species (Fig.
3A). Further analyses using transmission electron microscopy
(TEM) conﬁrmed that at 5 μM, WT α-Syn only forms mature
amyloid ﬁbrils after a long incubation time (8 d), whereas tet-
raubiquitinated α-Syn forms electron-dense aggregates that do not
possess an amyloid-like structure or morphology (Fig. 3B). These
amorphous tetra-Ub–α-Syn aggregates are already present at 84 h
but do not proceed to form amyloid ﬁbrils at longer incubation
times (Fig. 3B). These results suggest that the addition of a tetra-
Ub chain at K12 results in the formation of nonﬁbrillar aggregates
but blocks α-Syn ﬁbrillization in vitro.
Cross-Talk Between Ubiquitination and C-Terminal Phosphorylation.
Both immunohistochemical (17, 22) and proteomic studies (20)
have shown that α-Syn within LBs and other different inclusions
can be ubiquitinated and phosphorylated at S129 and/or at Y125
(17, 22, 30, 31). Interestingly, exogenously prepared α-Syn ﬁbrils
are rapidly ubiquitinated and phosphorylated at S129 upon in-
ternalization in mammalian cell lines and following stereotaxic
injection and uptake by neurons in mouse brain (32, 33). These
ﬁndings suggest potential cross-talk between α-Syn phosphory-
lation at S129 and Y125 and ubiquitination. Nonaka et al. (34)
suggested that S129 phosphorylation of α-Syn may not affect its
ubiquitination, using an in vitro assay based on E3 ligases present
in rabbit reticulocyte lysate. Recently, we showed that mono-
ubiquitination at K6 has no major impact on α-Syn phosphory-
lation at S87 by casein kinase I and at S129 by casein kinase I,
G protein-coupled receptor kinase 5, and polo-like kinase (PLK)
3 (6). To the best of our knowledge, the effects of polyubiqu-
itination on both serine and tyrosine phosphorylation of α-Syn
have not been investigated.
To determine whether the addition of Ub chains on N-ter-
minal region lysine residues could affect C-terminal phosphory-
lation of α-Syn, we ﬁrst investigated whether our semisynthetic
proteins could be phosphorylated by PLK3, which efﬁciently
phosphorylates α-Syn at S129 (35). Fig. 4A shows that no phos-
phorylation of S129 could be detected on K12 di- or tetraubi-
quitinated α-Syn, whereas monomeric unconjugated α-Syn used
as an internal control was efﬁciently phosphorylated at S129.
This suggests that the addition of a poly-Ub chain at K12 may
disrupt the interaction between α-Syn and PLKs, consistent with
previous studies from our group and others demonstrating that
the N-terminal domain of α-Syn is important for α-Syn–PLK2/3
interaction and PLK-mediated α-Syn phosphorylation (35). For
example, Wang et al. (36) showed that deletion of α-Syn’s ﬁrst
nine residues completely abolished its interaction and phos-
phorylation by PLK2.
To determine whether there could be cross-talks between di-
and tetraubiquitination at K12 and C-terminal tyrosine phos-
phorylation, we examined whether tetraubiquitinated α-Syn
could be phosphorylated by the nonreceptor spleen tyrosine ki-
nase (Syk), which is known to phosphorylate α-Syn at Y125,
Y133, and, to a lesser extent, Y136 (37). Fig. 4B shows that
diubiquitinated and tetraubiquitinated α-Syn are both phos-
phorylated at Y125 by Syk. However, both polyubiquitinated
α-Syn species are destabilized upon phosphorylation and exhibited
a tendency to precipitate, unlike WT α-Syn, which was used as an
Fig. 2. Purity and folding analyses of ubiquitinated α-Syn. (A) SDS/PAGE/
Coomassie staining of puriﬁed unconjugated (wt), mono-, di-, and tetrau-
biquitinated α-Syn. (B) SDS/PAGE/Western blot (WB) analysis of the same
proteins as in A. The primary antibodies are indicated below each blot. Ub-
conjugated α-Syn variants were puriﬁed using a 12% Tris·acetate GELFREE
cartridge (Expedeon). (C) Characterization of di- and tetra-Ub–α-Syn by CD,
in which wt (14.6 μM, black), di-Ub–α-Syn (6.71 μM, blue), and tetra-Ub–α-Syn
(4.85 μM, red) are shown. (D) Electrospray ionization MS of tetraubiquiti-
nated α-Syn was done to conﬁrm the identity of the protein (also Fig. S1B).
The observed mass of 48,634 Da is consistent with oxidation of the four me-
thionine residues within α-Syn to the sulfoxide form (calculated: 48,639.2 Da).
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internal control and remained soluble after Syk phosphorylation.
Moreover, phosphorylated tetraubiquitinated α-Syn is signiﬁcantly
more sensitive to destabilization than its diubiquitinated coun-
terpart, suggesting that the length of the K12-linked poly-Ub chain
may affect the stability and solubility of C-terminally tyrosine-
phosphorylated α-Syn (Fig. 4B, Lower). In the absence of Y125
phosphorylation and agitation, tetraubiquitinated α-Syn is stable
and does not aggregate (Fig. 4A). It is noteworthy that phosphor-
ylation at Y125 on its own does not inﬂuence the conformational
or aggregation properties of α-Syn signiﬁcantly (38). Together,
our results suggest that the combination of phosphorylation at
Y125 and tetraubiquitination renders α-Syn more susceptible to
aggregation and supports our hypothesis for cross-talk between
these two types of posttranslational modiﬁcations.
Effect of Mono-, Di-, and Tetraubiquitination on α-Syn Degradation
by the Proteasome. Several studies have shown that ubiquitination
plays an important role in regulating α-Syn degradation by the
proteasome (39–44). Interestingly, Tofaris et al. (45) showed that
ubiquitination of α-Syn by Nedd4 targets it for degradation via
the endosomal/lysosomal pathway. However, the nature of the
ubiquitination signal required for targeting α-Syn for proteaso-
mal or lysosomal degradation remained unexplored. Previous
studies have also suggested that the afﬁnity of protein-Ub
adducts for the proteasome increases with increasing length of
the poly-Ub chain, although a direct comparison using homo-
geneously modiﬁed substrates has not been possible (16).
Herein, we sought to determine the effect of mono-, di-, and
tetraubiquitination on the stability of α-Syn and its susceptibility
to degradation by the proteasome. Puriﬁed mono-, di-, and tet-
raubiquitinated α-Syn were incubated with fraction II, which
contains both 26S proteasomes and the entire cohort of deubi-
quitinases, and the extent of α-Syn deubiquitination and/or
degradation was assessed by monitoring the levels of these pro-
teins using Western blot analysis in the absence and presence of
the proteasome inhibitor MG132.
As shown in Fig. 5 A and B, di- and tetraubiquitinated α-Syn
are degraded efﬁciently by the proteasome in fraction II. In
contrast, in the case of monoubiquitinated α-Syn, the single Ub
moiety is efﬁciently cleaved well before the molecule is degraded
(Fig. 5C). These ﬁndings strongly suggest that a possible im-
portant role of the poly-Ub chain is to protect the adduct from
deubiquitinases activity and to enable a long enough residence
time of the conjugated substrate on the proteasome to allow its
efﬁcient degradation. We have previously shown that mono-
ubiquitinated α-Syn can be efﬁciently degraded by puriﬁed 26S
proteasome (7). The current experiment was carried out in crude
cell extract that contains both 26S proteasomes and the entire
cohort of deubiquitinases, which represents the intracellular
environment more faithfully. In the experiment carried out with
puriﬁed proteasome, soluble deubiquitinases were not present and
the proteasomal deubiquitinases were inhibited by o-phenan-
throlene as a metal chelator. Under these conditions, the mono-
ubiquitinated substrate was protected from all deubiquitinases
activities. It is still not clear whether the poly-Ub chain provides
true protection or whether its gradual cleavage allows the sub-
strate the time necessary for its capture and degradation by the
proteasome. It should be noted that the hypothesis that one role
of the poly-Ub chain is to provide protection against the activity
of deubiquitinases was previously raised by Schaefer and Morgan
(46). However, they demonstrated it on conjugates containing
chains with different lengths but not under conditions where the
deubiquitinases and the proteasomes are present in the system in
their physiological concentrations, allowing the two to “compete” in
displaying the effect of the chain length on the fate of the protein:
deubiquitination or degradation.
Discussion
Our ability to synthesize and conjugate site-speciﬁcally mono-,
di-, and tetra-Ub chains of deﬁned covalent structure has pro-
vided unique opportunities to elucidate the role of ubiquitination
in regulating α-Syn stability, aggregation, phosphorylation, and
clearance. Our observation that diubiquitinated α-Syn and tet-
raubiquitinated α-Syn, but not monoubiquitinated α-Syn, are
more resistant to deubiquitinases and are degraded by the
Fig. 3. Aggregation of tetraubiquitinated α-Syn. (A) wt and tetra-Ub–α-Syn
(50 μL) were incubated at 5 μM in 50 mM Tris and 150 mM NaCl (TBS) (pH 7.5)
with orbital shaking at 1,000 rpm. Aliquots (5 μL) were withdrawn at the
indicated time points, diluted to 10 μL with TBS, and centrifuged (20,000 × g,
10 min, 4 °C). The supernatant (7 μL) was loaded on SDS/PAGE gels for WB
analysis. (B) TEM analyses of uranyl acetate-stained samples analyzed after
84 h (Upper) and 8 d (Lower) of incubation. (Scale bars: 200 nm.)
Fig. 4. Interplay between di- and tetraubiquitination of α-Syn at K12 and
C-terminal phosphorylation. (A) K12 diubiquitination and K12 tetraubiqui-
tination abolish α-Syn phosphorylation at S129 by PLK3. wt α-Syn alone (4
μM) or added to 4 μM diubiquitinated/tetraubiquitinated α-Syn mixture as
an internal control was incubated with 0.42 μg of PLK3 and analyzed at the
indicated time points by SDS/PAGE/Western blot (WB). (Lower) Bands in-
dicated with an asterisk indicate bands not speciﬁc for pS129, because they
are detected at t = 0 before adding the kinase. (B) Phosphorylation of the
C-terminal tyrosines of α-Syn by SYK destabilizes tetraubiquitinated α-Syn,
whereas monomeric, unconjugated wt α-Syn remains stable. Puriﬁed wt,
diubiquitinated, or tetraubiquitinated α-Syn (3 μM) were incubated with
0.23 μg of SYK for the indicated time points and analyzed by SDS/PAGE/
WB. (Upper) Representative WBs from three independent experiments.
Lanes labeled “S” correspond to soluble fractions (supernatant after high-
speed centrifugation) at t = 48 h. (Lower) Quantiﬁcation of the band in-
tensities in three independent experiments. Asterisks indicate signiﬁcant
differences between the tetra-Ub–α-Syn levels compared with wt α-Syn (P <
0.05, paired t tests). D, di-Ub–α-Syn; T, tetra-Ub–α-Syn; U, unconjugated wt
α-Syn monomer.
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proteasome suggests that polyubiquitination serves as a signal for
α-Syn degradation by the proteasome.
Our ﬁndings are consistent with the emerging view that
ubiquitination is not required for α-Syn ﬁbrillization and LB
formation. This hypothesis is supported by previous studies
showing that not all α-Syn within LBs is ubiquitinated (19), as well
as our own ﬁndings that monoubiquitination stabilizes monomeric
α-Syn and tetraubiquitination favors the formation of nonﬁbrillar
aggregates. Furthermore, polyubiquitination of α-Syn by the E3
ligase carboxy-terminus of Hsp70-interacting protein (CHIP) in
a cell-free system and in cells results in signiﬁcant reduction of
the amount of insoluble α-Syn species (43) and oligomers (21).
These results suggest that mono- or polyubiquitination of α-Syn
inhibits its ﬁbrillization, and they are likely to occur after ﬁbril
formation. Interestingly, in vitro ubiquitination of preformed α-Syn
ﬁbrils results in mono- and diubiquitination patterns similar to
those observed in pathological brain samples (20). Finally, recent
studies showed that exogenous α-Syn ﬁbrils become rapidly
ubiquitinated upon internalization into neurons in culture as
well as in mouse brain (32, 33). Together, these results suggest
that ubiquitination of α-Syn may occur after α-Syn ﬁbril forma-
tion and could represent an active cellular response to disasso-
ciate these aggregates and/or promote clearance of α-Syn by
targeting it for degradation by the proteasome.
Despite several reports demonstrating that ubiquitinated
α-Syn is also phosphorylated at its C terminus (S129 and Y125)
(17, 22, 30, 31), the interplay across these modiﬁcations has not
previously been investigated. Our results demonstrate that the
effect of phosphorylation at Y125 on α-Syn aggregation is de-
pendent on the length of the poly-Ub chain. Tetraubiquitinated
α-Syn exhibited higher aggregation propensity than the diubiqui-
tinated α-Syn, whereas monoubiquitinated α-Syn does not aggre-
gate upon phosphorylation at Y125. The mechanism by which
phosphorylation enhances the aggregation of tetraubiquitinated
α-Syn is not clear, but it is plausible that the combination of
tetraubiquitination and phosphorylation at Y125 induces con-
formational changes that lead to the formation of an aggregation-
prone structure. These results suggest that α-Syn function in health
and/or disease could be under complex regulatory mechanisms
involving cross-talk among different posttranslational modiﬁcations.
The synthesis of tetraubiquitinated α-Syn represents an example
of a previously undescribed semisynthesis of a polyubiquitinated
protein of deﬁned covalent structure and is a signiﬁcant advance in
the ﬁelds of chemical synthesis of proteins and Ub research. These
advances, combined with recent improvements in Ub bioconjugate
synthesis, provide unique opportunities for introducing various
ﬂuorescent labels and chemical probes to enable investigation of the
role of the ubiquitination signal on the structure, function, and
interactome of proteins with spatial and temporal resolution. Our
work perfectly illustrates the power and potential of combining
synthetic protein chemistry enabled by modern chemical ligation
methods with recombinant DNA molecular biology to address fun-
damental questions in biochemistry and cell biology, especially the
all-important ﬁne details of the ubiquitination signaling pathways.
Materials and Methods
Generation of Tetraubiquitinated α-Syn at K12. Ligation of α-Syn[1–29(K12K*)]–
thioester and α-Syn[30–140(A30C)]. The ligation was carried out as previously
described for monoubiquitinated synuclein (6) starting from α-Syn[1–29
(K12K*)] peptide thioester (4.16 mg, 1.3 μmol) and α-Syn[30–140(A30C)] (10
mg, 0.87 μmol), generating the ligation product at a yield of ∼56% (7.1 mg).
Synthesis of Ub12–α-Syn(1–140). Puriﬁed peptide Ub2-Ub1-thioester (6.2 mg,
0.36 μmol) was dissolved in 69 μL of argon-purged 6 M guanidine·HCl and
200 mM phosphate buffer (pH ∼7.0). In a separate Eppendorf tube, the
α-Syn[1–140(K12K*)] (4 mg, 0.27 μmol) was dissolved in a 69-μL solution of
4-mercaptophenylacetic acid (MPAA) and TCEP (20 eq and 25 eq, respectively)
in argon-purged guanidine·HCl and phosphate buffer pH 7, and both solutions
were mixed together. The mixture was left at 37 °C for overnight. Sub-
sequently, the mixture was treated with methoxylamine·HCl (0.2 M) and TCEP
(30 eq) at pH 4 for 12 h at 37 °C to unmask the δ-mercaptolysine. The reaction
was followed by liquid chromatography MS using a C4 analytical column and
a gradient of 5–25–60% B over 45 min. For preparative HPLC, a similar gra-
dient was used to afford the ligation product Ub12–α-Syn(1–140) at a yield of
∼47% (4.0 mg).
Synthesis of Ub1234-Syn(1–140). Puriﬁed peptide Ub3-Ub4-thioester (2.8 mg,
0.16 μmol) was dissolved in 30 μL of argon-purged 6 M guanidine·HCl and
200 mM phosphate buffer (pH ∼7.0). In a separate Eppendorf tube, Ub12-Syn
[1–140(K12K*)] (4 mg, 0.13 μmol) was dissolved in a 33-μL solution of MPAA
and TCEP (20 eq and 25 eq, respectively) in argon-purged guanidine·HCl and
phosphate buffer (pH 7), and both solutions were mixed together. The
mixture was left at 37 °C overnight. The reaction was followed using an
analytical column and a gradient of 5–25–60% B over 45 min. For pre-
parative HPLC, a similar gradient was used to afford the ligation product
Ub1234–α-Syn(1–140) at a yield of ∼39% (2.4 mg).
Desulfurization. The reaction was carried out as previously described (15) to
afford desulfurized protein Ub1234–α-Syn(1–140) at a yield of 56% (1.3 mg).
In Vitro Phosphorylation Assays. Phosphorylation of WT and ubiquitinated
α-Syn was carried out by incubation of the proteins with 0.42 μg of PLK3
kinase (PV3812; Invitrogen) in 50 mM Hepes (pH 7.4) in the presence of
1 mM MgCl2, 1 mM EGTA, 2 mM Mg-ATP, and 1 mM DTT for 16 h at 30 °C in
a total volume of 50 μL. For the phosphorylation with PLK3, the substrate
protein concentration was 4 μM. Phosphorylation of WT and ubiquitinated
α-Syn at Y125 was carried out by incubation with 0.23 μg of Syk kinase
(PV3857; Invitrogen) in 50 mM Tris (pH 7.5) in the presence of 150 mM NaCl,
1 mMMgCl2, 1 mM EGTA, 2 mMMg-ATP, and 1 mM Na3VO4 for up to 48 h at
30 °C in a total volume of 50 μL. The ﬁnal substrate protein concentration
was 3 μM.
Degradation Assays. Puriﬁed α-Syn (∼0.5 μg), monoubiquitinated α-Syn (∼0.75
μg),diubiquitinatedα-Syn (∼1.0μg), and tetraubiquitinatedα-Syn (∼1.5μg)were
incubated at 37 °C for the indicated times in a reaction mixture containing in
a ﬁnal volume of 12.5 μL 25 μg of fraction II (Ub-depleted HeLa cell extract),
supplemented with ATP and the ATP-regenerating system as described pre-
viously (47). When indicated, the proteasome inhibitor MG132 was added at
a concentration of 100 μM. Reactions were terminated by the addition
of threefold concentrated sample buffer. Boiled samples were resolved via
Fig. 5. Proteasomal degradation of ubiquitinated α-Syn in a cell-free
reconstituted system. (A) Degradation of unconjugated (lanes 1–3), diubi-
quitinated (lanes 4–6), and tetraubiquitinated (lanes 7–9) α-Syn in crude
fraction II. The corresponding proteins were incubated in the presence of
crude fraction II for the indicated times in the absence or presence of the
proteasome inhibitor MG132 as speciﬁed. Following incubation, samples
were analyzed by SDS/PAGE/Western blot. (B) Repeat of the experiment
depicting the degradation of tetraubiquitinated α-Syn. In both experiments,
the percentage of remaining protein is shown. (C) Susceptibility of mono-
ubiquitinated α-Syn to the activity of deubiquitinases. α-Syn (lanes 1–4) and
monoubiquitinated α-Syn (lanes 5–9) were incubated for the indicated times
in the presence of crude fraction II in the presence and absence of the
proteasome inhibitor MG132. D, di-Ub–α-Syn; H, high-molecular weight spe-
cies; M, mono-Ub–α-Syn; T, tetra-Ub–α-Syn; U, unconjugated α-Syn monomer.
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SDS/PAGE (15%), and proteins were visualized after blotting to a nitrocellu-
lose membrane using anti–α-Syn antibody and chemiluminescence. Band in-
tensities were quantiﬁed using the Total Labs TL100 1D gel analysis software.
Aggregation Assays. Puriﬁed proteins [5 μM in Tris-buffered saline (TBS) buffer
(50 mM Tris, 150 mM NaCl [pH 7.5]) at a ﬁnal volume of 50 μL] were incubated
at 37 °C with orbital shaking at 1,000 rpm. For Western blot analyses, 5-μL
aliquots were diluted to 10 μL in TBS and centrifuged at 20,000 × g for 10 min
at 4 °C. The supernatant (7 μL) was mixed with 2× Laemmli sample buffer and
loaded on 15% SDS/PAGE gels. Western blot processing was done as described
above. For TEM analyses, 5-μL aliquots were mixed with 5 μL of TBS, and 5 μL
was deposited on Formvar/carbon-coated 200-mesh copper grids (Electron
Microscopy Sciences). Grids were then washed twice with 5 μL of ultrapure
water, stained twice with 5 μL of 2% (wt/vol) uranyl acetate (Electron Mi-
croscopy Sciences), and then vacuum-dried. Grids were imaged using a Tecnai
Spirit BioTWIN electron microscope equipped with a LaB6 source operated
at 80 kV. Digital micrographs were recorded with a 4096 × 4096 pixels FEI
Eagle CCD camera (FEI).
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